Osiboost 2: Using pharmacokinetics to improve cost-effectiveness of osimertinib treatment in non-small cell lung cancer
Description
OSIBOOST 2 is a clinical trial designed to enhance the cost-effectiveness of Osimertinib for patients with Non-Small Cell Lung Cancer (NSCLC). Although Osimertinib significantly improves progression-free survival compared to older EGFRm-targeted therapies, its high cost remains a concern. To address this, the trial investigates the use of the CYP3A4 inhibitor Cobicistat, which reduces the metabolism of Osimertinib and increases its exposure (a process known as pharmacokinetic boosting). This approach may potentially make the treatment more affordable without compromising its efficacy.
Who is the principal investigator?
Dr. Sander Croes
Team
Drs. Paul Kruithof (coordinating investigator)
Drs. Maud Salmans
Dr. Robin van Geel
Prof. Dr. Lizza Hendriks
Who is collaborating?
Erasmus MC
Antoni van Leeuwenhoek Hospital
University Medical Centre Groningen
Zuyderland MC
Relevant link
Contact for internship or collaboration
Dr. Sander Croes (s.croes@mumc.nl)
Also, visit our Vacancies page.
Contact for general questions
Drs. Paul Kruithof (Paul.kruithof@mumc.nl)